SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News ),
developer of advanced diagnostic products, announced today that it has begun
shipping its second-generation instrument, the NanoChip® 400, both domestically
and to Europe. The general laboratory system for molecular biology applications
utilizes the company's improved NanoChip® 400-site electronic microarray,
upon which homebrew molecular assays can be developed in clinical and research
laboratories. Building on features customers valued with the first-generation
NanoChip® Molecular Biology Workstation and 100-site chip, the new multi-purpose
system combines sample and reagent handling robotics with detection in an instrument
half the size of its predecessor. The open and robust platform creates the opportunity
for laboratories to use one system for multiple molecular applications, including
the detection of single nucleotide polymorphisms (SNPs) and multi-gene targets
like those tested for pharmacogenetics.
The NanoChip® 400 cartridge used with the system
is a blank microarray template that constructs the
user defined panel of genetic markers on one chip
at the time of sample testing. The cartridge has
400 test sites that can be used for any combination
of multiple genes and multiple samples and can be
used multiple times until the 400 test sites are
used. This cartridge reusability makes the NanoChip® 400
system easier and more cost-effective to use than
research-grade thousand-gene chip arrays and more
suitable than polymerase chain reaction (PCR) when
multi-allele or multi-gene assays are of interest.
The system is ideal for mid- to high-volume laboratories
where the need to streamline testing and workflow
is a high priority.
"I am very excited about the new instrument," said
Steve Cook, manager of molecular diagnostics at Lahey
Clinic in Boston. "I think it is going to be great
for us as a customer and great for Nanogen as a vendor.
The walk-away capability will be a valuable improvement
over the Molecular Biology Workstation and will allow
us to consolidate and streamline our workflow. This
capability may open up the instrument for us to do
more homebrew designs."
"Our first deliveries of the NanoChip® 400 system
mark a significant milestone in the development of
our company," said Howard C. Birndorf, Nanogen chairman
and CEO. "Moving products out of development and
into our commercial product portfolio will contribute
significantly to our revenue in the coming quarters.
We're delighted to be able to offer new tools that
facilitate the understanding of disease and can ultimately
be used to improve the health of patients."
The NanoChip 400® is manufactured by Nanogen's
long-standing collaborator Hitachi Instruments Group
under the Food and Drug Administration's Quality
System Regulation. Nanogen has self-certified the
instrument for European CE Mark. Additional information
is available by calling 877-NANOGEN or by visiting www.nanogen.com .
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers,
clinicians and physicians worldwide with improved
methods and tools to predict, diagnose, and ultimately
help treat disease. The company's products include
real-time PCR reagents, the NanoChip® electronic
microarray platform and a line of rapid diagnostic
tests. Nanogen's ten years of pioneering research
involving nanotechnology holds the promise of miniaturization
and continues to be supported for its potential for
diagnostic and biowarfare applications. For additional
information please visit Nanogen's website at www.nanogen.com .
This press release contains forward-looking statements
that are subject to risks and uncertainties that
could cause actual results to differ materially from
those set forth in the forward-looking statements,
including whether products under development can
be successfully developed and commercialized, whether
patents owned or licensed by Nanogen will be developed
into products, whether the patents owned by Nanogen
offer any protection against competitors with competing
technologies, whether results reported by our customers
or partners can be identically replicated, and other
risks and uncertainties discussed under the caption "Factors
That May Affect Results" and elsewhere in Nanogen's
Form 10-K or Form 10-Q most recently filed with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Nanogen
disclaims any intent or obligation to update these
Source: Nanogen, Inc.